Jorvinl Wart and Corn Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of warts, including plantar warts, flat warts, common warts, corns, and calluses.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage is 1 ml administered twice daily. This regimen should be maintained for a total duration of 15 days. Healthcare professionals should ensure that the administration is performed consistently at the same times each day to maintain optimal therapeutic levels.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected, as this may exacerbate the condition. The product should not be used in individuals with known allergies to any of its ingredients to prevent adverse reactions. It is also contraindicated for use on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes due to the potential for irritation or complications.

Patients with diabetes or poor blood circulation should avoid use, as these conditions may impair healing and increase the risk of adverse effects. Additionally, the product is contraindicated in pregnant or breastfeeding individuals unless specifically directed by a healthcare practitioner, to ensure safety for both the mother and child.

Warnings and Precautions

For external use only. This product is flammable; therefore, it must be kept away from fire and flame. It is essential to keep this product out of reach of children to prevent accidental ingestion or misuse.

Healthcare professionals should advise patients to avoid contact with the eyes. In the event of contact, it is crucial to flush the eyes with plenty of cool water. The product should not be swallowed; if ingestion occurs, immediate medical attention should be sought, or the Poison Control Center (1-800-222-1222) should be contacted.

This product should not be applied to irritated skin or any area that is infected. Additionally, it is contraindicated for use in individuals who are allergic to any ingredient in the formulation. The product must not be used on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes.

Patients with diabetes or poor blood circulation should refrain from using this product. Furthermore, it is advised that pregnant or breastfeeding individuals only use this product if directed by a healthcare practitioner.

Patients should be instructed to discontinue use and contact their healthcare provider if they experience any of the following symptoms: chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, or swelling of the hands or feet. Regular monitoring of these symptoms is recommended to ensure patient safety.

Side Effects

Patients using this product may experience a range of adverse reactions. Serious adverse reactions that warrant immediate discontinuation of use include chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, and swelling of the hands or feet. In the event of any of these symptoms, patients are advised to stop use and seek medical attention.

Additionally, it is important to note that this product is for external use only and is flammable. Patients should keep it away from fire and flame, and out of reach of children. Contact with the eyes should be avoided; if contact occurs, patients should flush the eyes with plenty of cool water. The product should not be ingested; if swallowed, patients should seek medical attention or contact a Poison Control Center immediately at 1-800-222-1222.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Jorvinl Wart and Corn Remover (salicylic acid 40%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. It is important to instruct caregivers not to allow children to swallow the medication; in the event of accidental ingestion, immediate medical attention should be sought or the Poison Control Center (1-800-222-1222) contacted.

The medication should be stored at room temperature, avoiding exposure to excessive heat above 37°C (99°F). It is contraindicated for use on irritated skin or any area that is infected. Additionally, pregnant or breastfeeding individuals should consult a healthcare practitioner before use unless directed otherwise.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should use this medication only if directed by a healthcare practitioner. The potential risks associated with the use of this medication during pregnancy and lactation have not been fully established. Therefore, healthcare providers should carefully consider the benefits and risks before prescribing this medication to women of childbearing potential. It is essential to discuss any potential impacts on fetal outcomes and breastfeeding with patients to ensure informed decision-making.

Lactation

Lactating mothers should consult a healthcare practitioner before using this medication while breastfeeding. There is no available data on the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is advised when administering this medication to lactating mothers.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data regarding its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters have not been defined.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of vital signs and clinical status is essential to ensure patient safety.

Healthcare professionals should also consider consulting a poison control center or relevant toxicology resources for guidance on management strategies tailored to the specific circumstances of the overdosage event.

Nonclinical Toxicology

If a patient is pregnant or breastfeeding, it is advised to consult a healthcare practitioner before use, as teratogenic effects may be a concern. No non-teratogenic effects have been reported in the available data. Additionally, there is no information provided regarding nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to store the product at room temperature and to avoid exposure to excessive heat above 37°C (99°F). Patients should be informed that skin discoloration may occur during or after use.

It is essential to instruct patients not to use the product on irritated skin or any area that is infected. Patients should be cautioned against using the product if they are allergic to any of its ingredients, or on moles, birthmarks, warts with hair growing from them, genital warts, or warts on the face or mucous membranes. Additionally, patients with diabetes or poor blood circulation, as well as those who are pregnant or breastfeeding, should only use the product if directed by a healthcare practitioner.

Patients should be advised to discontinue use and seek medical attention if they experience chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, or swelling of the hands or feet.

When instructing patients on how to use the product, they should be guided to clean the affected area thoroughly. Soaking the area in warm water for 5 minutes is optional. Patients should then dip the provided brush into the liquid and apply it to the affected area, ensuring complete coverage before allowing it to dry. This process should be repeated 2-3 times daily until the skin appears smooth. Patients should be made aware that more severe cases may require a longer duration of treatment, and they should be encouraged to exercise patience and perseverance. The maximum continuous use period should not exceed 12 weeks.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that the storage environment does not exceed temperatures of 37°C (99°F). Care should be taken to avoid exposure to excessive heat, as this may compromise the integrity of the product.

Additional Clinical Information

Patients should administer the medication at a dosage of 1 ml twice daily, with a total supply for 15 days. Clinicians should advise patients to store the medication at room temperature and to avoid exposure to excessive heat above 37°C (99°F). It is important to inform patients that skin discoloration may occur during or after the use of the medication.